https://www.selleckchem.com/pr....oducts/z-4-hydroxyta
1% [95% CI 75.1-94.2], 46.8% [36.1-60.8] and 17.6% [6.32-49.2] for the low-, intermediate, and high-risk groups, respectively; 3-year PFS, 70.6% [59.4-83.8], 35.9% [25.9-49.8], and 7.35% [1.16-46.7] for the low-, intermediate, and high-risk groups, respectively). The PINK-B model was further validated in an independent cohort. Serum β2M is an independent prognostic factor for ENKTL patients. The new serum β2M-based prognostic model may be useful for identifying ultra-high-risk patients, and it can easily be adopted into dai
Like
Comment
Share
